Sort   by:  
 Page size 
GenomicsChromatin accessibility in MC38/gp100 cells after type I PRMT inhibitor treatment
Chromatin accessibility in MC38/gp100 cells after type I PRMT inhibitor treatment
PRJNA679893 | ENA
GenomicsMC38/gp100 cells after type I PRMT inhibitor treatment
MC38/gp100 cells after type I PRMT inhibitor treatment
PRJNA679810 | ENA
GenomicsTumor intrinsic PRMT5 inhibition through MTAP loss predicts response to the first-in-class type I PRMT inhibitor, GSK3368715
Tumor intrinsic PRMT5 inhibition through MTAP loss predicts response to the first-in-class type I PRMT inhibitor, GSK3368715
PRJNA522801 | ENA
GenomicsDifferential expression genes analysis in MC38/gp100 cell line with DMSO or type I PRMT inhibitor treatment
Differential expression genes analysis in MC38/gp100 cell line with DMSO or type I PRMT inhibitor treatment
PRJNA679894 | ENA
GenomicsRNA-seq of murine small intestinal organoids treated with type I PRMT inhibitor MS023 against untreated controls
RNA-seq of murine small intestinal organoids treated with type I PRMT inhibitor MS023 against untreated controls
PRJEB39183 | ENA
ProteomicsChanges in protein arginine methylation by GSK3368712
Type I Protein Arginine Methyltransferases (PRMTs) catalyze asymmetric dimethylation of arginine residues on numerous proteins. Type I PRMTs and their substrates have been implicated in human cancers, suggesting that inhibiting Type I PRMT activity offers a tractable approach for therapeutic interve...
ORGANISM(S): Homo sapiens (Human) 
2019-09-10 | PXD012747 | Pride
Lc-msms Human Arginine methyltransferases Cancer cell lines Immunoproteomic Antibody Type i prmt Methylscan 
TranscriptomicsTumor intrinsic PRMT5 inhibition through MTAP loss predicts response to the first-in-class type I PRMT inhibitor, GSK3368715
Type I Protein Arginine Methyltransferases (PRMTs) catalyze asymmetric dimethylation of arginine (ADMA) residues on numerous protein substrates to modulate their activity. Type I PRMTs and many of their substrates have been implicated in human cancers, suggesting that inhibiting Type I PRMT activity...
ORGANISM(S): Homo sapiens 
2019-08-15 | GSE126651 | GEO
TranscriptomicsRNA-seq of murine small intestinal organoids treated with type I PRMT inhibitor MS023 against untreated controls
Murine small intestinal organoids were cultured in the presence or absence of 5µM inhibitor MS023 (PubChem CID 92136227), which targets type I protein arginine methyltransferases Prmt1, Prmt3, Prmt4, Prmt6, Prmt8. Organoids were grown in culture media containing EGF, Noggin and R-spondin (ENR), medi...
ORGANISM(S): Mus musculus 
2020-12-16 | E-MTAB-9291 | biostudies-arrayexpress
GenomicsChromatin accessibility in MC38/gp100 cells after type I PRMT inhibitor treatment
Immunotherapies have produced dramatic responses in reducing tumor growth and prolonging overall survival to unprecedented rates in melanoma, lung cancer, renal cancer and mismatch repair deficient colon cancer patients. Despite approvals for immune checkpoint inhibitors in a wide range of cancers, ...
ORGANISM(S): Mus musculus 
2022-11-01 | GSE161909 | GEO
TranscriptomicsDifferential expression genes analysis in MC38/gp100 cell line with DMSO or type I PRMT inhibitor treatment
Immunotherapies have produced dramatic responses in reducing tumor growth and prolonging overall survival to unprecedented rates in melanoma, lung cancer, renal cancer and mismatch repair deficient colon cancer patients. Despite approvals for immune checkpoint inhibitors in a wide range of cancers, ...
ORGANISM(S): Mus musculus 
2022-11-01 | GSE161908 | GEO
Sort   by:  
 Page size